Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Frederick L. Locke(Moffitt Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Lori A. Leslie(Hackensack University Medical Center), Leo I. Gordon(Northwestern University), Marco Schupp(Amgen (Switzerland)), Yin Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Marie José Kersten(Hovon), Simone Filosto(Kite (United States)), Caron A. Jacobson(Dana-Farber Cancer Institute), John M. Pagel(University of Washington), Olalekan O. Oluwole(Vanderbilt University), Tom van Meerten(University Medical Center Groningen), Monique C. Minnema(University Medical Center Utrecht), Joseph P. McGuirk(University of Kansas Medical Center), Jina Shah(University of Maryland, Baltimore), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Patrick M. Reagan(University of Rochester), Peter Vandenberghe(KU Leuven), Aaron P. Rapoport(University of Maryland, Baltimore), Christina To, Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Armin Ghobadi(Washington University in St. Louis), Paul Cheng(Cardiovascular Institute of the South), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Umar Farooq(Wake Forest University), Michael Dickinson(The University of Melbourne), Kevin Song(Vancouver General Hospital), David B. Miklos(Stanford University), Ian W. Flinn(Tennessee Oncology), Sridhar Chaganti(Cutaneous Lymphoma Foundation), Peter A. Riedell(University of Chicago)
Cited by 1,571
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k